Plant Name: Fissistigma oldhamii
Taxonomic Information:
Plant ID: NPO18509
Plant Latin Name: Fissistigma oldhamii
Taxonomy Genus: Fissistigma
Taxonomy Family: Annonaceae
Plant External Links:
NCBI TaxonomyDB:
453234
Plant-of-the-World-Online:
73046-1
Used in Medicines:
Unknown.
Geographical Distribution:
Taiwan; Vietnam; Cambodia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HTR7; HTR2A; HTR1A; | |
| CDK2; CDK4; AURKB; AURKA; CDK1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Protein Kinase | CDK2 | Cyclin-dependent kinase 2 | P24941 | CHEMBL301 |
| Protein Kinase | CDK4 | Cyclin-dependent kinase 4 | P11802 | CHEMBL331 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.152E-08 | 5.711E-05 | HTR1A, HTR2A, HTR7 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.409E-07 | 2.556E-04 | HTR1A, HTR2A, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.409E-07 | 2.556E-04 | HTR1A, HTR2A, HTR7 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 2.540E-07 | 3.951E-04 | HTR1A, HTR2A, HTR7 |
| MF | GO:0005488; binding | GO:0030332; cyclin binding | 3.123E-07 | 4.251E-04 | CDK1, CDK2, CDK4 |
| MF | GO:0003824; catalytic activity | GO:0004693; cyclin-dependent protein serine/threonine kinase activity | 4.544E-07 | 5.679E-04 | CDK1, CDK2, CDK4 |
| CC | GO:0044464; cell part | GO:0000307; cyclin-dependent protein kinase holoenzyme complex | 7.390E-07 | 6.705E-04 | CDK1, CDK2, CDK4 |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 1.157E-06 | 9.334E-04 | HTR1A, HTR7 |
| MF | GO:0005488; binding | GO:0008144; drug binding | 1.394E-06 | 1.084E-03 | AURKA, AURKB, CDK1, CDK2, CDK4, CYP2D6, HTR2A |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 1.620E-06 | 1.175E-03 | AURKA, AURKB, CDK1 |
| CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 1.928E-06 | 1.312E-03 | AURKA, AURKB |
| BP | GO:0009987; cellular process | GO:0006977; DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | 2.609E-06 | 1.387E-03 | AURKA, CDK1, CDK2 |
| MF | GO:0003824; catalytic activity | GO:0035174; histone serine kinase activity | 2.892E-06 | 1.431E-03 | AURKA, AURKB |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 4.834E-06 | 2.105E-03 | AURKA, CDK1, CDK4 |
| BP | GO:0008152; metabolic process | GO:0031145; anaphase-promoting complex-dependent catabolic process | 5.644E-06 | 2.276E-03 | AURKA, AURKB, CDK1 |
| BP | GO:0009987; cellular process | GO:0010972; negative regulation of G2/M transition of mitotic cell cycle | 9.179E-06 | 3.276E-03 | AURKA, AURKB, CDK1 |
| BP | GO:0008152; metabolic process | GO:0035404; histone-serine phosphorylation | 1.271E-05 | 4.177E-03 | AURKA, AURKB |
| CC | GO:0043226; organelle | GO:0000780; condensed nuclear chromosome, centromeric region | 1.271E-05 | 4.177E-03 | AURKA, AURKB |
| CC | GO:0043226; organelle | GO:0031616; spindle pole centrosome | 1.271E-05 | 4.177E-03 | AURKA, AURKB |
| BP | GO:0051179; localization | GO:0034501; protein localization to kinetochore | 1.501E-05 | 4.540E-03 | AURKB, CDK1 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 2.109E-05 | 5.812E-03 | HTR1A, HTR2A, HTR7 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 2.180E-05 | 5.910E-03 | CDK1, CDK2, CDK4, HTR1A, HTR2A |
| BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 3.298E-05 | 7.485E-03 | AURKA, CDK1, CDK4 |
| BP | GO:0065007; biological regulation | GO:0051100; negative regulation of binding | 4.109E-05 | 8.772E-03 | AURKA, AURKB, CYP2D6 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.149E-07 | 3.907E-06 | HTR7, CYP2D6, HTR1A, HTR2A |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04115 | p53 signaling pathway | 3.253E-06 | 5.529E-05 | CDK4, CDK2, CDK1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.856E-05 | 1.616E-04 | CDK2, CDK1, AURKA |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.902E-05 | 1.616E-04 | CDK4, CDK2, CDK1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 8.518E-05 | 5.792E-04 | CDK4, CDK2, CDK1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.075E-04 | 1.176E-03 | HTR7, HTR1A, HTR2A |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 6.452E-04 | 2.870E-03 | CDK4, CDK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 8.366E-04 | 3.161E-03 | CDK2, CDK1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 6.754E-04 | 2.870E-03 | CDK1, HTR2A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.842E-03 | 5.695E-03 | CDK4, CDK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.602E-03 | 5.445E-03 | CDK4, CDK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 2.782E-03 | 7.678E-03 | HTR7, HTR2A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 3.488E-03 | 8.470E-03 | CDK2, CDK1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 2.936E-03 | 7.678E-03 | CDK2, CDK1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR1A; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1A; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CDK2; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | CDK2; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HTR1A; |
| NA: NA | Episode | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| NA: NA | Addiction | NA | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; |
| NA: NA | Social phobia | NA | HTR1A; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CDK2; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; HTR2A; HTR1A; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CDK2; CDK1; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
| C00-D49: Neoplasms | Thymoma | C37, D15.0 | CDK2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
